HC Wainwright Issues Pessimistic Forecast for DNLI Earnings

Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Stock analysts at HC Wainwright dropped their FY2027 EPS estimates for Denali Therapeutics in a note issued to investors on Thursday, November 7th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings per share of $1.68 for the year, down from their previous estimate of $1.69. HC Wainwright has a "Buy" rating and a $90.00 price target on the stock. The consensus estimate for Denali Therapeutics' current full-year earnings is ($2.53) per share.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same quarter in the previous year, the firm posted ($0.72) earnings per share.

A number of other equities analysts have also recently weighed in on DNLI. Bank of America upped their price objective on shares of Denali Therapeutics from $25.00 to $29.00 and gave the stock a "buy" rating in a research report on Wednesday, September 4th. Citigroup raised their price target on shares of Denali Therapeutics from $26.00 to $32.00 and gave the company a "buy" rating in a research note on Friday, August 2nd. JPMorgan Chase & Co. reduced their target price on Denali Therapeutics from $29.00 to $28.00 and set an "overweight" rating for the company in a report on Friday, October 11th. Raymond James reaffirmed a "market perform" rating on shares of Denali Therapeutics in a research note on Thursday, October 10th. Finally, Jefferies Financial Group increased their price objective on Denali Therapeutics from $40.00 to $45.00 and gave the company a "buy" rating in a research note on Friday, November 1st. Three analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $38.90.

Denali Therapeutics Stock Up 2.1 %

Shares of Denali Therapeutics stock traded up $0.61 on Friday, reaching $30.21. The company's stock had a trading volume of 212,710 shares, compared to its average volume of 1,068,645. The company has a market capitalization of $4.32 billion, a P/E ratio of -10.39 and a beta of 1.40. The stock has a 50-day moving average price of $27.67 and a 200-day moving average price of $23.40. Denali Therapeutics has a 52-week low of $14.56 and a 52-week high of $32.13.

Hedge Funds Weigh In On Denali Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its position in shares of Denali Therapeutics by 1.2% during the first quarter. Vanguard Group Inc. now owns 10,968,293 shares of the company's stock worth $225,069,000 after purchasing an additional 133,810 shares in the last quarter. Capital Research Global Investors lifted its holdings in Denali Therapeutics by 107.9% during the 1st quarter. Capital Research Global Investors now owns 6,049,957 shares of the company's stock worth $124,145,000 after buying an additional 3,140,429 shares in the last quarter. Baker BROS. Advisors LP boosted its position in Denali Therapeutics by 43.1% in the 1st quarter. Baker BROS. Advisors LP now owns 3,731,695 shares of the company's stock valued at $76,574,000 after buying an additional 1,124,499 shares during the period. Marshall Wace LLP grew its stake in shares of Denali Therapeutics by 12.7% in the second quarter. Marshall Wace LLP now owns 2,418,833 shares of the company's stock worth $56,165,000 after acquiring an additional 272,454 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its position in shares of Denali Therapeutics by 6.3% during the second quarter. Dimensional Fund Advisors LP now owns 1,417,472 shares of the company's stock worth $32,913,000 after acquiring an additional 84,522 shares during the period. Hedge funds and other institutional investors own 92.92% of the company's stock.

Insider Activity

In other news, Director Steve E. Krognes sold 30,000 shares of the stock in a transaction that occurred on Monday, September 30th. The shares were sold at an average price of $29.03, for a total value of $870,900.00. Following the completion of the sale, the director now owns 29,096 shares of the company's stock, valued at $844,656.88. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, Director Steve E. Krognes sold 30,000 shares of the stock in a transaction on Monday, September 30th. The stock was sold at an average price of $29.03, for a total transaction of $870,900.00. Following the completion of the transaction, the director now directly owns 29,096 shares in the company, valued at approximately $844,656.88. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Ryan J. Watts sold 40,000 shares of the business's stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $27.69, for a total transaction of $1,107,600.00. Following the completion of the sale, the chief executive officer now owns 235,807 shares in the company, valued at approximately $6,529,495.83. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 7.90% of the company's stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.